CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic range proteinuria

Liu, Hongxia; Xu, Qinxia; Huang, Wenyan; Zhao, Qi; Jiang, Zhihu; Kuang, Xinyu; Li, Zhiling; Sun, Huajun; Qiu, Xiaoyan

doi:10.1007/s00228-019-02726-w

Cited by 5 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CYP3A , one of the major CYP families, encodes for various catalyzing enzymes involved in many drug metabolism including nifedipine, cyclosporine, tacrolimus, erythromycin, midazolam, alprazolam, and triazolam [ 20 , 21 ]. For CYP3A5 , the CYP3A5*3 allele results in the absence of protein expression due to an improper mRNA splicing [ 22 ]. CYP3A5*3 (rs776746) was highly present in Caucasians (85–95%), Mexicans (75%), and Asians (65–85%) and to a lower degree in African Americans (27–55%) [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Genotypic and phenotypic landscapes of 51 pharmacogenes derived from whole-genome sequencing in a Thai population

Wankaew

Chariyavilaskul²,

Chamnanphon³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

Differences in drug responses in individuals are partly due to genetic variations in pharmacogenes, which differ among populations. Here, genome sequencing of 171 unrelated Thai individuals from all regions of Thailand was used to call star alleles of 51 pharmacogenes by Stargazer, determine allele and genotype frequencies, predict phenotype and compare high-impact variant frequencies between Thai and other populations. Three control genes, EGFR, VDR, and RYR1, were used, giving consistent results. Every individual had at least three genes with variant or altered phenotype. Forty of the 51 pharmacogenes had at least one individual with variant or altered phenotype. Moreover, thirteen genes had at least 25% of individuals with variant or altered phenotype including SLCO1B3 (97.08%), CYP3A5 (88.3%), CYP2C19 (60.82%), CYP2A6 (60.2%), SULT1A1 (56.14%), G6PD (54.39%), CYP4B1 (50.00%), CYP2D6 (48.65%), CYP2F1 (46.41%), NAT2 (40.35%), SLCO2B1 (28.95%), UGT1A1 (28.07%), and SLCO1B1 (26.79%). Allele frequencies of high impact variants from our samples were most similar to East Asian. Remarkably, we identified twenty predicted high impact variants which have not previously been reported. Our results provide information that contributes to the implementation of pharmacogenetic testing in Thailand and other Southeast Asian countries, bringing a step closer to personalized medicine.

show abstract